scientific articles

ESMO Patient Guide Series based on the ESMO Clinical Practice Guidelines

This guide has been prepared to help you, as well as your friends, family and caregivers, better understand non-small-cell lung cancer (NSCLC) and its treatment. It contains information on the different subtypes of NSCLC, the causes of the disease and how it is diagnosed, up-to-date guidance on the types of treatments that may be available and any possible side effects of treatment.

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Biomarker testing is essential to identify subgroups of NSCLC with oncogenic drivers that can be therapeutically targeted. These drivers are mainly found in lung adenocarcinomas(LUADs). Demonstration of the specific molecular alteration is necessary to tailor treatment with the appropriate targeted therapy. The frequency of oncogenic drivers in NSCLC as well as general discussion of testing strategy and methodology, including the use of liquid biopsies

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Pathological diagnosis and subtyping are carried out according to the World Health Organization (WHO) guidelines